DrugDashboards

Market view

insulin aspart · Injection, Solution

20 marketed package NDCs · 4 active manufacturers

Most dispensed: 100 [iU]/mL · Injection, Solution · #5 syringe, plastics/carton / 3 ml in 1 syringe, plastic · 100 [iU]/mL · Injection, Suspension · #5 syringe, plastics/carton / 3 ml in 1 syringe, plastic · 100 [iU]/mL · Injection, Solution · #1 vial, glass/carton / 10 ml in 1 vial, glass · 100 [iU]/mL · Injection, Suspension · #1 vial, glass/carton / 10 ml in 1 vial, glass

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble. The price has held steady around $8.57 per mL over the past year. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

Price range and competition

RSS: changes for this drug

Every company selling this drug reports its own price. The line follows the middle of the pack; the shaded band holds the middle half of companies — the wider it is, the more they disagree.

$0$20.00$40.00Jul 2013Sep 202604companies actively selling

Latest · Sep 2026 — typical price $8.57 · middle half $7.76$8.75 · full range $6.94$8.96 · 7 products · 4 companies

middle half of companies’ pricestypical (median) pricecompanies actively selling (bottom lane)Priced per mLSource: CMS NADAC
ⓘ How this was built
Data sources
  • CMS NADAC weekly survey + monthly archives back to 2013 (data.medicaid.gov)
  • CMS Federal Upper Limit files (weighted AMP)
  • FDA NDC Directory (openFDA) — maker roster
Method

Each month's band spans the NADAC unit prices of every NDC of this drug (min, quartiles, median, max), split into brand and generic cohorts by FDA marketing category. Maker counts come from distinct labelers with the NDC actively listed.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

What changed in the last 90 days

Every detected change for insulin aspart, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.

  • NovologAug 19, 2026
    Price down
    NADAC $6.93804 → $6.93614 per unit (-0.03%)
  • NovologAug 19, 2026
    Price down
    NADAC $8.93737 → $8.93569 per unit (-0.02%)
  • NovoLog Mix 70/30Aug 19, 2026
    Price down
    NADAC $8.94106 → $8.93906 per unit (-0.02%)
  • NovoLog Mix 70/30Aug 19, 2026
    Price down
    NADAC $6.92882 → $6.92777 per unit (-0.02%)
  • NovologAug 19, 2026
    Price up
    NADAC $8.56966 → $8.57338 per unit (+0.04%)
  • FiaspAug 19, 2026
    Price up
    NADAC $8.57252 → $8.57314 per unit (+0.01%)
  • NovoLog Mix 70/30Jul 22, 2026
    Price down
    NADAC $8.94275 → $8.94106 per unit (-0.02%)
  • NovologJul 22, 2026
    Price down
    NADAC $8.93837 → $8.93737 per unit (-0.01%)
  • NovologJul 22, 2026
    Price down
    NADAC $6.93907 → $6.93804 per unit (-0.01%)
  • NovologJul 22, 2026
    Price down
    NADAC $8.57149 → $8.56966 per unit (-0.02%)

Same drug class

Other molecules FDA puts in Insulin Analog, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.

Common questions

Is Insulin aspart in shortage right now?
No. FDA does not currently list Insulin aspart in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
Who makes Insulin aspart?
7 companies have marketed Insulin aspart in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
What does Insulin aspart cost?
The typical pharmacy pays about $8.57 per mL, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.

Shortage reports for this molecule

  • Planned discontinuationInsulin Aspart, Injection, 10 mL Insulin Aspart vial (NDC 73070-100-11)Jul 21, 2025
  • Planned discontinuationInsulin Aspart, Injection, 3 mL Insulin Aspart FlexPen® (NDC 73070-103-15)Jul 21, 2025
  • Planned discontinuationInsulin Aspart, Injection, 3 mL Insulin Aspart PenFill® cartridge (NDC 73070-102-15)Jul 21, 2025

All marketed products

Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.